Selcia awarded GMP certificate for preparation and carbon-14 labelling of APIs for clinical trials
Commenting on the award, Selcia’s Managing Director, Dr Hans Fliri said: “With market demand increasing for GMP radiolabelling, we are pleased that we can now offer pharmaceutical and biotech companies cost effective radiolabelling services to support both the pre-clinical and clinical development of their new medicines. Selcia’s extended capability of now being able to produce GMP radiolabelled API material will shorten the timeframe for our clients to commence key Phase 1 clinical trials”.
Director of Radiochemistry Dr Gill Little said: “Our radiochemistry team continues to focus on delivering the best possible tailored service. Together with our GLP analytical laboratory we can supply the high quality products that our customers expect”.
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.